Supply of Regadenoson

Summary

The tender concerns the successive supply of Regadenoson 400 micrograms in 5 ml vials for human infusion, used in cardiac magnetic resonance studies at the cardiovascular research laboratory of CNIC. The estimated quantity is 6,000 vials, with deliveries expected for studies conducted between November 2026 and November 2029. The estimated contract value is EUR 174,964 excluding VAT, while the base tender budget is EUR 56,440 excluding VAT. Price is the only award criterion and carries 100 points. The supplier must provide a legally authorised human-use medicine meeting applicable health, safety, quality, traceability and storage requirements. Deliveries must be made to the Pharmacy Service of Hospital Carlos III, C/ Sinesio Delgado, 10. Standard orders must be delivered within 7 calendar days and urgent orders within 48 hours. The supplier bears transport, logistics, temporary storage and technical assistance costs and must provide a delivery note containing the order number, procurement reference, product description and quantity. Participation requires a minimum annual turnover of EUR 84,660, relevant supply experience of at least EUR 39,508 in the highest-performing year within the last three years, and liability or professional indemnity insurance with minimum cover of EUR 1,500,000. The winning bidder must provide a final guarantee equal to 5% of the contract price excluding VAT. Electronic submission is mandatory, variants are not allowed, and any planned subcontracting must be identified in the tender.